Literature DB >> 11267753

Leishmania infantum-specific IgG, IgG1 and IgG2 antibody responses in healthy and ill dogs from endemic areas. Evolution in the course of infection and after treatment.

L Solano-Gallego1, C Riera, X Roura, L Iniesta, M Gallego, J E Valladares, R Fisa, S Castillejo, J Alberola, L Ferrer, M Arboix, M Portús.   

Abstract

The expression of IgG, IgG1 and IgG2 specific antibodies for Leishmania infantum was studied in five groups of dogs in Catalonia (Spain): I, 99 asymptomatic dogs (infected and uninfected) from a highly endemic area for leishmaniosis; II, 139 untreated dogs with clinically patent leishmaniosis; III, 11 naturally infected asymptomatic dogs monitored for up to 5 years since they were found seropositive to Leishmania antigen and without treatment; IV, 25 naturally infected dogs with clinically patent leishmaniosis and treated with either meglumine antimoniate and allopurinol or allopurinol alone and V, six experimentally infected dogs, treated with meglumine antimoniate and controlled for 5 years. The levels (ELISA units) of IgG, IgG1 and IgG2 in asymptomatic dogs (group I) were very variable (24+/-33, 32+/-31 and 26+/-31, respectively), and, as expected, lower than in ill dogs (group II) (168+/-34, 84+/-71 and 172+/-31, respectively). In both groups, the correlation between IgG and IgG2 levels (r=0.95, P<0.001 in group I and r=0.63, P<0.001 in group II) was higher than between IgG and IgG1 levels (r=0.01, P>0.05 in group I and r=0.31, P<0.001 in group II). In group III, IgG and IgG2 expression increased during infection, while IgG1 expression remained the same. In dogs of group IV, IgG levels after 1 year of treatment decreased more in responsive (mean values, 163+/-42 before treatment (b.t.) and 100+/-36 after treatment (a.t.)) than in unresponsive dogs (158+/-29 b.t. and 124+/-51 a.t.), especially for IgG1 (94+/-89 b.t. and 20+/-21 a.t. in responsive dogs and 35+/-25 b.t. and 22+/-13 a.t. in unresponsive dogs) rather than for IgG2 (156+/-16 b.t. and 114+/-45 a.t. in responsive and 151+/-11 b.t. and 125+/-36 a.t. in unresponsive dogs). Similar results were observed in the evolution of experimentally infected animals after consecutive and specific treatments. Overall results show the great variation in Leishmania-specific IgG1 expression in asymptomatic and symptomatic dogs, their lack of correlation with that of IgG2 and chemotherapy is more effective in dogs with initially high expression of IgG1.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11267753     DOI: 10.1016/s0304-4017(00)00446-5

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  38 in total

1.  Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis.

Authors:  E Carrillo; S Ahmed; K Goldsmith-Pestana; J Nieto; Y Osorio; B Travi; J Moreno; D McMahon-Pratt
Journal:  Vaccine       Date:  2006-11-10       Impact factor: 3.641

2.  Dynamics and predictive potential of antibodies against insect-derived recombinant Leishmania infantum proteins during chemotherapy of naturally infected dogs.

Authors:  Felicitat Todolí; Inmaculada Galindo; Silvia Gómez-Sebastián; Mariano Pérez-Filgueira; José M Escribano; Jordi Alberola; Alhelí Rodríguez-Cortés
Journal:  Am J Trop Med Hyg       Date:  2010-05       Impact factor: 2.345

3.  A cross-sectional study on canine Leishmania (L.) infantum chagasi infection in Amazonian Brazil ratifies a higher prevalence of specific IgG-antibody response than delayed-type hypersensitivity in symptomatic and asymptomatic dogs.

Authors:  Fernando T Silveira; Liliane A Carneiro; Patrícia K S Ramos; Eugênia J Chagas; Luciana V R Lima; Marliane B Campos; Márcia D Laurenti; Claudia M C Gomes; Carlos E P Corbett
Journal:  Parasitol Res       Date:  2012-06-16       Impact factor: 2.289

4.  Serum indirect immunofluorescence assay and real-time PCR results in dogs affected by Leishmania infantum: evaluation before and after treatment at different clinical stages.

Authors:  Barbara Bruno; Angelo Romano; Renato Zanatta; Simona Spina; Walter Mignone; Francesco Ingravalle; Paola Barzanti; Lara Ceccarelli; Maria Goria
Journal:  J Vet Diagn Invest       Date:  2019-01-13       Impact factor: 1.279

5.  Serological diagnosis of canine leishmaniosis: comparison of three commercially available tests.

Authors:  Denis Wolf; Klaus Failing; Anja Taubert; Nikola Pantchev
Journal:  Parasitol Res       Date:  2014-04-10       Impact factor: 2.289

6.  Epidemiological implications of the use of various methods for the diagnosis of canine leishmaniasis in dogs with different characteristics and in differing prevalence scenarios.

Authors:  Manuel Morales-Yuste; Francisco Morillas-Márquez; Victoriano Díaz-Sáez; Sergio Barón-López; Carmen Acedo-Sánchez; Joaquina Martín-Sánchez
Journal:  Parasitol Res       Date:  2012-01-10       Impact factor: 2.289

7.  Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.

Authors:  Marta Mateo; Laurence Maynard; Claudia Vischer; Paolo Bianciardi; Guadalupe Miró
Journal:  Parasitol Res       Date:  2009-02-24       Impact factor: 2.289

8.  First study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the treatment of canine leishmaniosis due to Leishmania infantum.

Authors:  Leticia Hernández; Rosa Gálvez; Ana Montoya; Rocio Checa; Alba Bello; Tom Bosschaerts; Herwig Jansen; Cristina Rupérez; Anny Fortin; Guadalupe Miró
Journal:  Parasitol Res       Date:  2013-11-06       Impact factor: 2.289

9.  Detection of anti-Leishmania immunoglobulin G antibodies in urine specimens of dogs with leishmaniasis.

Authors:  L Solano-Gallego; A Rodríguez; L Iniesta; M Arboix; M Portús; J Alberola
Journal:  Clin Diagn Lab Immunol       Date:  2003-09

10.  Effectiveness of the sesquiterpene (-)-α-bisabolol in dogs with naturally acquired canine leishmaniosis: an exploratory clinical trial.

Authors:  V Corpas-López; G Merino-Espinosa; C Acedo-Sánchez; V Díaz-Sáez; M C Navarro-Moll; F Morillas-Márquez; J Martín-Sánchez
Journal:  Vet Res Commun       Date:  2018-02-16       Impact factor: 2.459

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.